Current opinion in oncology · 2025
Systemic therapy of nonsmall cell lung cancer: breakthroughs during the last five decades.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pirker Robert, Zhou Caicun
Аннотация
PURPOSE OF REVIEW: The purpose of this review is to summarize the breakthroughs in the systemic treatment of patients with nonsmall cell lung cancer (NSCLC) during the last five decades.
RECENT FINDINGS: Chemotherapy was established in metastatic, locally advanced and early-stage NSCLC. Tyrosine kinase inhibitors have become standard for palliative and adjuvant therapy in patients with driver mutation-positive NSCLC. Immune checkpoint inhibitors were established in operable, locally advanced and metastatic NSCLC. Antiemetics, hematopoietic growth factors, bisphosphonates and opioids improved palliative care.
SUMMARY: Breakthroughs in the systemic therapy of NSCLC during the last five decades included chemotherapy, targeted therapies, immune checkpoint inhibitors and better supportive care.
RECENT FINDINGS: Chemotherapy was established in metastatic, locally advanced and early-stage NSCLC. Tyrosine kinase inhibitors have become standard for palliative and adjuvant therapy in patients with driver mutation-positive NSCLC. Immune checkpoint inhibitors were established in operable, locally advanced and metastatic NSCLC. Antiemetics, hematopoietic growth factors, bisphosphonates and opioids improved palliative care.
SUMMARY: Breakthroughs in the systemic therapy of NSCLC during the last five decades included chemotherapy, targeted therapies, immune checkpoint inhibitors and better supportive care.